[go: up one dir, main page]

ATE305455T1 - 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität - Google Patents

1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität

Info

Publication number
ATE305455T1
ATE305455T1 AT96911969T AT96911969T ATE305455T1 AT E305455 T1 ATE305455 T1 AT E305455T1 AT 96911969 T AT96911969 T AT 96911969T AT 96911969 T AT96911969 T AT 96911969T AT E305455 T1 ATE305455 T1 AT E305455T1
Authority
AT
Austria
Prior art keywords
pdeiv
dihydro
imidazole
derivatives
inhibiting activity
Prior art date
Application number
AT96911969T
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Gaston Stanislas Marcell Diels
Jose Ignacio Andres-Gil
Francisco Javi Fernandez-Gadea
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE305455T1 publication Critical patent/ATE305455T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96911969T 1995-04-06 1996-03-28 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität ATE305455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200870 1995-04-06
PCT/EP1996/001393 WO1996031487A1 (en) 1995-04-06 1996-03-28 1,3-dihydro-2h-imidazol-2-one derivatives having pde iv and cytokinin inhibiting activity

Publications (1)

Publication Number Publication Date
ATE305455T1 true ATE305455T1 (de) 2005-10-15

Family

ID=8220175

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96911969T ATE305455T1 (de) 1995-04-06 1996-03-28 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität

Country Status (15)

Country Link
US (1) US5869515A (de)
EP (1) EP0832071B1 (de)
JP (1) JP4115519B2 (de)
KR (1) KR100400159B1 (de)
CN (1) CN1103760C (de)
AR (1) AR002984A1 (de)
AT (1) ATE305455T1 (de)
CA (1) CA2216542C (de)
DE (1) DE69635224T2 (de)
ES (1) ES2250988T3 (de)
IL (1) IL117806A (de)
MY (1) MY117936A (de)
TW (1) TW375612B (de)
WO (1) WO1996031487A1 (de)
ZA (1) ZA962753B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
SI0934280T1 (en) * 1996-10-02 2003-12-31 Janssen Pharmaceutica N.V. Pde iv inhibiting 2-cyanoiminoimidazole derivatives
JP4778612B2 (ja) * 1998-04-01 2011-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐｄｅｉｖ阻害ピリジン誘導体
BRPI0013478B8 (pt) 1999-08-21 2016-12-27 Altana Pharma Ag medicamento compreendendo inibidor pde e uso de roflumilast
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
WO2005105763A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
US20080070867A1 (en) * 2005-01-19 2008-03-20 Metabasis Therapeutics, Inc. 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases
EP1987009A1 (de) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cycloharnstoffverbindung als calciumkanalblocker

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636516A (en) * 1981-02-19 1987-01-13 Yamanouchi Pharmaceutical Co., Ltd. 3,5-di-tert-butyl-4-hydroxyphenyl-substituted heterocyclic compounds
BR8603845A (pt) * 1985-08-13 1987-03-24 Sumitomo Chemical Co Derivado de acido butenoico,composicao herbicida,processo para controlar ou exterminar ervas daninhas indesejaveis,uso do dito derivado,compostos intermediarios para o mesmo e processo para preparar tal derivado
US4845233A (en) * 1987-09-11 1989-07-04 Iprx, Inc. Imidazolin-2-ones
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
EP0652868B1 (de) * 1992-07-28 2004-11-10 Aventis Pharma Limited Inhibitoren von c-amp phosphodiesterase
ATE218549T1 (de) * 1993-07-28 2002-06-15 Aventis Pharma Ltd Verbindungen als pde iv und tnf inhibitoren
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
ATE217865T1 (de) * 1994-06-24 2002-06-15 Euro Celtique Sa Verbindungen zur hemmung von phosphodiesrerase iv

Also Published As

Publication number Publication date
CA2216542A1 (en) 1996-10-10
AU5497996A (en) 1996-10-23
MY117936A (en) 2004-08-30
DE69635224T2 (de) 2006-06-22
DE69635224D1 (de) 2006-02-09
KR100400159B1 (ko) 2003-12-31
EP0832071A1 (de) 1998-04-01
IL117806A (en) 2000-02-17
EP0832071B1 (de) 2005-09-28
JPH11504003A (ja) 1999-04-06
IL117806A0 (en) 1996-08-04
ZA962753B (en) 1997-10-06
WO1996031487A1 (en) 1996-10-10
AR002984A1 (es) 1998-05-27
CN1181073A (zh) 1998-05-06
JP4115519B2 (ja) 2008-07-09
KR19980703448A (ko) 1998-11-05
CN1103760C (zh) 2003-03-26
TW375612B (en) 1999-12-01
US5869515A (en) 1999-02-09
CA2216542C (en) 2009-01-13
AU697390B2 (en) 1998-10-01
ES2250988T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
CY2005010I1 (el) Ο - αλκυλιωμενα παραγωγα ραπαμυκινης και η χρηση τους, ιδιαιτερως ως ανοσοκατασταλτικων
DE69619661D1 (de) 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-on-derivate mit pde iv-und cytokin-inhibisender aktivität
EG19187A (en) Quinazoline derivatives and their use as fungicide.
NL350016I1 (nl) 3-Aryl-4-hydroxy-delta#3-dihydrofuranon-en 3-aryl-4-hydroxy-delta#3-dihydrothiofenon-derivaten.
MX9204301A (es) Acilmercaptoalcanoildipeptidos, metodos de preparacion y su uso terapeutico.
NL300295I2 (nl) 3,3-diarylpropylaminen, de toepassing en bereidinghiervan
ZA976222B (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their use.
ATE225342T1 (de) Benzofuran-derivate und deren verwendung
MX9201681A (es) 4,5-dihidro-1h-pirazol-1-carboxiamidas 3,4,n-sustituidas y su uso como inseticidas.
FI954491A (fi) Heterosykliä sisältäviä amidiinijohdokset, niiden valmistus ja käyttö
TR199800117A3 (tr) Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.
DE69832184D1 (de) O-substituierte hydroxycumaranonderivate mit antitumoraler und antimetastatischer wirkung
DE68910113D1 (de) Wachstuminhibierendes mittel und dessen verwendung.
DE69424051D1 (de) Rapamycin-derivat mit antimikrobe, antikrebs und immunomodulatorischer aktivität
DK0721457T3 (da) 2',5'-Oligoadenylat-2',3'-cyclophosphater og 2',5'-oligo-adenylater med antipapillomavirusaktivitet
FI952063A (fi) Peneemejä, joissa 6-metyyleeni on substituoitu, ja välituotteita
MX9203459A (es) Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
DE69637363D1 (de) 1,3-dihydro-1-(phenylalkenyl)-2h-imidazol-2 on-derivate mit pde iv und cytokin-inhibirendes aktivität
ATE305455T1 (de) 1,3-dihydro-2h-imidazol-2-on-derivate mit pdeiv und cytokin inhibierender aktivität
EP0640093A4 (de) Menschlisches crabp-i und crabp-ii.
FI894552A (fi) Anordning i gasregulator.
DE69712425D1 (de) Naphthalin-Derivate, Zwischenprodukte und Verwendungen
BR9508669A (pt) Novos derivados de taizoloÚ3,2-a¾quinolina e naftirina
TR24169A (tr) Benzohidroksamik tuerevleri, bunlarin herbisitler olarak kullanilmasi vebunlari
ITMI922071A0 (it) Derivati xantonici, loro preparazione ed attivita'

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0832071

Country of ref document: EP